	Application No.	Applicant(s)
Notice of Allowability	10/725,349	MUJICA-FERNAUD ET AL.
	Examiner	Art Unit
	Celia Chang	1625
The MAILING DATE of this communication appeal claims being allowable, PROSECUTION ON THE MERITS IS therewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIP of the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in this app or other appropriate communication IGHTS. This application is subject to	olication. If not included will be mailed in due course. THIS
1. This communication is responsive to April 19, 2007.		
2. ☑ The allowed claim(s) is/are <u>1-7,29-32 and 34</u> .		
3. Acknowledgment is made of a claim for foreign priority ur a) All b) Some* c) None of the: 1. Certified copies of the priority documents have 2. Certified copies of the priority documents have 3. Copies of the certified copies of the priority documents have International Bureau (PCT Rule 17.2(a)). * Certified copies not received: Applicant has THREE MONTHS FROM THE "MAILING DATE" noted below. Failure to timely comply will result in ABANDONN THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 4. A SUBSTITUTE OATH OR DECLARATION must be subm	e been received. e been received in Application No cuments have been received in this a of this communication to file a reply MENT of this application. eitted. Note the attached EXAMINER	national stage application from the complying with the requirements
INFORMAL PATENT APPLICATION (PTO-152) which give		tion is deficient.
 CORRECTED DRAWINGS (as "replacement sheets") must be submitted. (a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached 		
· 1) ☐ hereto or 2) ☐ to Paper No./Mail Date		
(b) including changes required by the attached Examiner	s Amendment / Comment or in the C	Office action of
Paper No./Mail Date Identifying indicia such as the application number (see 37 CFR 1 each sheet. Replacement sheet(s) should be labeled as such in t		
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
	·	
 Attachment(s) 1. ☑ Notice of References Cited (PTO-892) 2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948) 3. ☐ Information Disclosure Statements (PTO/SB/08),	 5. ☐ Notice of Informal P 6. ☐ Interview Summary Paper No./Mail Dat 7. ☒ Examiner's Amendr 8. ☒ Examiner's Statemen 9. ☐ Other 	(PTO-413), te <u>attached</u>
·		Art Unit 1625

Application/Control Number: 10/725,349

Art Unit: 1625

DETAILED ACTION

Page 2

1. Amendments and response filed by applicants dated April 19, 2007 have been entered and considered carefully.

Claims 8-10, 12-13, 17, 19-20, 26-27 and 33 are cancelled. Claims 1-7, and 34 being drawn to the elected invention are pending. Claims 11, 14-16, 18, 21-25, 28-32 stayed withdrawn as being drawn to the non-elected invention.

2. Examiner's Amendment

Authorization for this examiner's amendment was given in a telephone interview with Mr. Csaba Henter on Jun. 28, 2007.

Claim 7. line 1, after the term *comprising*, insert the term

--therapeutically effective amount of—

Claim 11, 14-16, 18, 21-25, 18 being drawn to the non-elected invention, are canceled without prejudice against applicants' filing of divisional applications.

Claim 29. line 1, after the term *comprising*, insert the term

--an effective amount of—

line 1, after the term *claim 1*, insert the term

-- and a cosmetically acceptable exipient—

Claim 30, line 1-2, delete the term "and therein the proteins of the skin from stress" and in its place insert

-- from oxidative stress or damage from the sun—

Claim 31-32. line 2, change the dependency to claim 29.

Art Unit: 1625

3.

Reason for allowance

The following is an examiner's statement of reasons for allowance:

Applicants have amended the compounds to the specific and enabled compounds described in the specification, thus, obviated the 112 rejections. Descriptions for the therapeutically effective amount is on page 49 wherein IC 50 of exemplified compounds were found. The prior art has well recognized that benzopyranone compounds are useful in cosmetic composition for treating oxidative stress (see recitation on PTO-892) and descriptive support for the cosmetic use of the compound are found on specification p.14 and 43. Claims 1-7, 29-32 and 34 are allowed.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

4. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Celia Chang whose telephone number is 571-272-0679. The examiner can normally be reached on Monday through Thursday from 8:30 am to 5:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Janet L. Andres, Ph. D., can be reached on 571-272-0867. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

OACS/Chang July 2, 2007 Celia Chang
Primary Examiner
Art Unit 1625